Market Cap 5.42B
Revenue (ttm) 385.69M
Net Income (ttm) -287.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.47%
Debt to Equity Ratio 3.41
Volume 525,200
Avg Vol 650,956
Day's Range N/A - N/A
Shares Out 49.24M
Stochastic %K 69%
Beta 0.46
Analysts Strong Sell
Price Target $175.61

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 332 3241
Fax: 212 320 0245
Address:
One World Trade Center, 22nd Floor, New York, United States
Mike826_1999
Mike826_1999 Jul. 17 at 1:16 PM
$AXSM July 16th issue of Inflammopharmacology Migraine is among the most frequently observed neurovascular malady affecting almost 1 billion people globally and is defined by frequent episodes of headache, accompanying neurological problems, and a markedly reduced standard of health. Migraine pathogenesis is directly linked to the CGRP (Calcitonin-gene-related-peptide), a strong vasodilating protein entangled in the exchange of nociceptor signals, and the cyclo-oxygenase (COX) enzymes, influencing inflammatory responses which aggravate migraine manifestations. Although COX inhibiting drugs as well as CGRP receptor blockers have therapeutical advantages when administered independently, however, they also have drawbacks, such as insufficient effectiveness or side effects, highlighting the necessity of synergistic approaches. In this regard, SYMBRAVO is a unique combinatorial pharmacological approach that aims to combine the advantages of COX-2 suppression and CGRP regulation. Continued
1 · Reply
jozef56
jozef56 Jul. 17 at 12:23 PM
$AXSM they just closed a loan !!!
0 · Reply
A_Train1
A_Train1 Jul. 17 at 3:53 AM
$AXSM are psychedelics the reason AXSM is stuck in the mud? https://www.cnn.com/2025/07/16/health/psychedelics-ibogaine-trump-kennedy
1 · Reply
Vakeshka
Vakeshka Jul. 16 at 7:03 PM
$AXSM smarter institutions keep adding. "...BVF Inc. IL grew its stake in shares of Axsome Therapeutics by 21.8% now owns 1,690,221 shares of the company's stock worth $197,130,000 after acquiring an additional 302,157 shares during the period. Geode Capital Management LLC lifted its holdings in Axsome Therapeutics by 0.4% now owns 912,538 shares of the company's stock valued at $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Invesco Ltd. boosted its position in Axsome Therapeutics by 23.8% now owns 857,001 shares of the company's stock worth $99,952,000 after purchasing an additional 164,537 shares. Wellington Management Group LLP increased its stake by 4.5% now owns 703,279 shares of the company's stock worth $82,023,000 after purchasing an additional 30,122. Finally, Hood River Capital Management LLC raised its position in shares of Axsome Therapeutics by 3.2% now owns 644,785 shares of the company's stock valued at $54,555,000 ..."
0 · Reply
Vakeshka
Vakeshka Jul. 16 at 6:52 PM
$AXSM average analysts revenue, earnings, and free cash flow projections from Simply Wall.st Note the consensus forecast for the company to breakeven on both earnings and free cash flow around mid to 3Q next year. Ignore near-term noise and volatility, imho some of us will be kicking ourselves next year for not having more at these levels.
0 · Reply
Vakeshka
Vakeshka Jul. 15 at 8:16 PM
$AXSM the current price seems a bit disconnected from the $175 or so average analyst PT. I asked ChatGPT for the average actual price in 1H24 vs. the average analyst price in that period (12-mo would be to 1H25). So the average actual price in 1H24 was $78 against the average analyst PT of $132. Technically we hit $130+ in 1Q25 so the analysts were generally correct. If recent history repeats itself, we should see $170+ in the next 12 months or so.
1 · Reply
jozef56
jozef56 Jul. 15 at 1:57 PM
$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts
0 · Reply
lvdfll
lvdfll Jul. 15 at 1:57 PM
$AXSM chatgpt is bullish on this
0 · Reply
Quantumup
Quantumup Jul. 15 at 1:18 PM
Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:
0 · Reply
JeffTex
JeffTex Jul. 15 at 9:32 AM
$AXSM just a hunch. They hv some good news & can’t wait till ER
0 · Reply
Latest News on AXSM
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 10:41 AM EDT - 2 months ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1


Axsome: The Alzheimer's Agitation Program For AXS-05

Mar 21, 2025, 11:36 AM EDT - 4 months ago

Axsome: The Alzheimer's Agitation Program For AXS-05


Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 20, 2025, 8:15 AM EST - 5 months ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering


Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 11:12 AM EST - 5 months ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript


US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:55 PM EST - 5 months ago

US FDA approves Axsome Therapeutics' migraine drug


Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 9:15 AM EST - 7 months ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results


Axsome Therapeutics: Lots Of Moving Parts

Jul 23, 2024, 4:06 AM EDT - 1 year ago

Axsome Therapeutics: Lots Of Moving Parts


Mike826_1999
Mike826_1999 Jul. 17 at 1:16 PM
$AXSM July 16th issue of Inflammopharmacology Migraine is among the most frequently observed neurovascular malady affecting almost 1 billion people globally and is defined by frequent episodes of headache, accompanying neurological problems, and a markedly reduced standard of health. Migraine pathogenesis is directly linked to the CGRP (Calcitonin-gene-related-peptide), a strong vasodilating protein entangled in the exchange of nociceptor signals, and the cyclo-oxygenase (COX) enzymes, influencing inflammatory responses which aggravate migraine manifestations. Although COX inhibiting drugs as well as CGRP receptor blockers have therapeutical advantages when administered independently, however, they also have drawbacks, such as insufficient effectiveness or side effects, highlighting the necessity of synergistic approaches. In this regard, SYMBRAVO is a unique combinatorial pharmacological approach that aims to combine the advantages of COX-2 suppression and CGRP regulation. Continued
1 · Reply
jozef56
jozef56 Jul. 17 at 12:23 PM
$AXSM they just closed a loan !!!
0 · Reply
A_Train1
A_Train1 Jul. 17 at 3:53 AM
$AXSM are psychedelics the reason AXSM is stuck in the mud? https://www.cnn.com/2025/07/16/health/psychedelics-ibogaine-trump-kennedy
1 · Reply
Vakeshka
Vakeshka Jul. 16 at 7:03 PM
$AXSM smarter institutions keep adding. "...BVF Inc. IL grew its stake in shares of Axsome Therapeutics by 21.8% now owns 1,690,221 shares of the company's stock worth $197,130,000 after acquiring an additional 302,157 shares during the period. Geode Capital Management LLC lifted its holdings in Axsome Therapeutics by 0.4% now owns 912,538 shares of the company's stock valued at $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Invesco Ltd. boosted its position in Axsome Therapeutics by 23.8% now owns 857,001 shares of the company's stock worth $99,952,000 after purchasing an additional 164,537 shares. Wellington Management Group LLP increased its stake by 4.5% now owns 703,279 shares of the company's stock worth $82,023,000 after purchasing an additional 30,122. Finally, Hood River Capital Management LLC raised its position in shares of Axsome Therapeutics by 3.2% now owns 644,785 shares of the company's stock valued at $54,555,000 ..."
0 · Reply
Vakeshka
Vakeshka Jul. 16 at 6:52 PM
$AXSM average analysts revenue, earnings, and free cash flow projections from Simply Wall.st Note the consensus forecast for the company to breakeven on both earnings and free cash flow around mid to 3Q next year. Ignore near-term noise and volatility, imho some of us will be kicking ourselves next year for not having more at these levels.
0 · Reply
Vakeshka
Vakeshka Jul. 15 at 8:16 PM
$AXSM the current price seems a bit disconnected from the $175 or so average analyst PT. I asked ChatGPT for the average actual price in 1H24 vs. the average analyst price in that period (12-mo would be to 1H25). So the average actual price in 1H24 was $78 against the average analyst PT of $132. Technically we hit $130+ in 1Q25 so the analysts were generally correct. If recent history repeats itself, we should see $170+ in the next 12 months or so.
1 · Reply
jozef56
jozef56 Jul. 15 at 1:57 PM
$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts
0 · Reply
lvdfll
lvdfll Jul. 15 at 1:57 PM
$AXSM chatgpt is bullish on this
0 · Reply
Quantumup
Quantumup Jul. 15 at 1:18 PM
Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:
0 · Reply
JeffTex
JeffTex Jul. 15 at 9:32 AM
$AXSM just a hunch. They hv some good news & can’t wait till ER
0 · Reply
Doozio
Doozio Jul. 15 at 3:44 AM
$AXSM $$$ pattern retest out of 🐑⏰♾️ during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jul. 15 at 3:43 AM
Wen $IWM $XBI lead da 🧠 spreads on steroids. Better $AXSM body during 🐒🍌🧠⏰♾️!
0 · Reply
Vakeshka
Vakeshka Jul. 14 at 10:40 PM
$AXSM smart money keeps buying. "Edgestream Partners L.P. purchased a new stake in shares of Axsome Therapeutics, Inc., according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 70,086 shares of the company's stock, valued at approximately $8,174,000. Edgestream Partners L.P. owned 0.14% of Axsome Therapeutics at the end of the most recent quarter."
1 · Reply
Mike826_1999
Mike826_1999 Jul. 14 at 8:42 PM
$AXSM Thanks to fellow investor BB. https://www.axsomemedicalaffairs.com/wp-content/uploads/2025/07/Diamond-Migraine-2025_INTERCEPT-by-MIDAS_print.pdf https://www.axsomemedicalaffairs.com/wp-content/uploads/2025/07/Diamond-Migraine-2025_INTERCEPT-by-MIDAS_print.pdf
0 · Reply
GA09
GA09 Jul. 14 at 4:05 PM
$AXSM The next acquisition could be AXSM for anywhere between $15B & $20B.
4 · Reply
A_Train1
A_Train1 Jul. 14 at 2:38 PM
$AXSM so controlled for the last several months despite much higher reaffirming PTs.
0 · Reply
rpmotox1
rpmotox1 Jul. 14 at 2:17 PM
$AXSM that a girl..... make us proud!
0 · Reply
Vakeshka
Vakeshka Jul. 14 at 11:18 AM
$AXSM BofA maintains Buy rating with $173 PT.
0 · Reply
jozef56
jozef56 Jul. 13 at 12:25 PM
$AXSM economics is a delicate balance of a lot of variables. Import taxes as 30% to the EU will backfire big time and will lead in short time to higher consumer prices. Even worse ....on long term these countries will take their actions to become more independent from the US. Everyone will agree except....... Thank you Trumpie
3 · Reply
SteveJohnsonis
SteveJohnsonis Jul. 13 at 2:19 AM
0 · Reply
quickaspeter
quickaspeter Jul. 12 at 5:37 PM
$AXSM Excellent news…now, let’s go! 💥🚀💰
0 · Reply
Mike826_1999
Mike826_1999 Jul. 11 at 11:39 PM
$AXSM AXSM reached and RSI of 85 https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-axsome-therapeutics-earns-85-rs-rating/
0 · Reply